NO2680834T3 - - Google Patents

Info

Publication number
NO2680834T3
NO2680834T3 NO12710026A NO12710026A NO2680834T3 NO 2680834 T3 NO2680834 T3 NO 2680834T3 NO 12710026 A NO12710026 A NO 12710026A NO 12710026 A NO12710026 A NO 12710026A NO 2680834 T3 NO2680834 T3 NO 2680834T3
Authority
NO
Norway
Application number
NO12710026A
Other languages
Norwegian (no)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of NO2680834T3 publication Critical patent/NO2680834T3/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/06Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/107Emulsions ; Emulsion preconcentrates; Micelles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Dispersion Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
NO12710026A 2011-05-03 2012-03-02 NO2680834T3 (https=)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP11003603 2011-05-03

Publications (1)

Publication Number Publication Date
NO2680834T3 true NO2680834T3 (https=) 2018-03-17

Family

ID=44652117

Family Applications (1)

Application Number Title Priority Date Filing Date
NO12710026A NO2680834T3 (https=) 2011-05-03 2012-03-02

Country Status (24)

Country Link
US (3) US9446008B2 (https=)
EP (3) EP2680834B1 (https=)
JP (3) JP6027549B2 (https=)
KR (2) KR102039320B1 (https=)
CN (1) CN103501774A (https=)
AU (2) AU2012224954C1 (https=)
BR (1) BR112013022556A8 (https=)
CA (1) CA2828637C (https=)
CY (1) CY1119725T1 (https=)
DK (1) DK2680834T3 (https=)
EA (2) EA025194B1 (https=)
ES (2) ES2654407T3 (https=)
HR (1) HRP20171836T1 (https=)
HU (1) HUE037491T2 (https=)
IL (2) IL227826B (https=)
LT (1) LT2680834T (https=)
MX (2) MX374468B (https=)
NO (1) NO2680834T3 (https=)
PL (1) PL2680834T3 (https=)
PT (2) PT2680834T (https=)
RS (1) RS56692B1 (https=)
SI (1) SI2680834T1 (https=)
WO (1) WO2012119729A1 (https=)
ZA (1) ZA201306480B (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101946790B1 (ko) 2011-03-04 2019-02-13 그뤼넨탈 게엠베하 경구 투여를 위한 타펜타돌의 수성 약제학적 제형
RS56692B1 (sr) * 2011-03-04 2018-03-30 Gruenenthal Gmbh Polučvrsta vodena farmaceutska kompozicija koja sadrži tapentadol
US9395306B2 (en) 2011-08-05 2016-07-19 Halliburton Energy Services, Inc. Methods for monitoring fluids within or produced from a subterranean formation during acidizing operations using opticoanalytical devices
US8997860B2 (en) 2011-08-05 2015-04-07 Halliburton Energy Services, Inc. Methods for monitoring the formation and transport of a fracturing fluid using opticoanalytical devices
US8619256B1 (en) 2012-09-14 2013-12-31 Halliburton Energy Services, Inc. Systems and methods for monitoring the properties of a fluid cement composition in a flow path
US20140076550A1 (en) 2012-09-14 2014-03-20 Halliburton Energy Services, Inc. Systems and Methods for Detecting Microannulus Formation and Remediation
US9228940B2 (en) 2012-09-14 2016-01-05 Halliburton Energy Services, Inc. Systems, methods, and apparatuses for in situ monitoring of cement fluid compositions and setting processes thereof
WO2015014980A1 (en) * 2013-08-02 2015-02-05 Ratiopharm Gmbh Composition comprising tapentadol in a dissolved form
EP2845625A1 (en) 2013-09-04 2015-03-11 Grünenthal GmbH Tapentadol for use in the treatment of fibromyalgia and chronic fatigue syndrome
EP3273953B1 (en) 2015-03-27 2019-01-02 Grünenthal GmbH Stable formulation for parenteral administration of tapentadol
CN109996533A (zh) 2016-09-23 2019-07-09 格吕伦塔尔有限公司 用于肠胃外施用他喷他多的稳定制剂
JP2021532112A (ja) * 2018-07-24 2021-11-25 ドクトア・アウグスト・ボルフ・ゲーエムベーハー・ウント・コンパニー・カー・ゲー−アルツナイミツテル 抗コリン性化合物の局所用エマルション
EP3846852A4 (en) 2018-09-07 2022-06-15 R.P. Scherer Technologies, LLC Solid or semisolid lipid based dosage form stabilization through curing and addition of low hlb surfactant(s)
EP3941422A4 (en) 2019-03-18 2023-04-19 Sunstar Americas, Inc. ORAL CARE COMPOSITION

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4775678A (en) * 1984-10-01 1988-10-04 Schering Corporation Clotrimazole cream
DE4426245A1 (de) 1994-07-23 1996-02-22 Gruenenthal Gmbh 1-Phenyl-3-dimethylamino-propanverbindungen mit pharmakologischer Wirkung
US6183758B1 (en) * 1998-01-29 2001-02-06 Highland Laboratories, Inc. Phytochemicals, nutrients & medication absorption &/or treatment
US6399087B1 (en) 2000-12-20 2002-06-04 Amphastar Pharmaceuticals, Inc. Propofol formulation with enhanced microbial inhibition
DE10109763A1 (de) 2001-02-28 2002-09-05 Gruenenthal Gmbh Pharmazeutische Salze
US20050176790A1 (en) 2001-02-28 2005-08-11 Johannes Bartholomaus Pharmaceutical salts
PE20030527A1 (es) 2001-10-24 2003-07-26 Gruenenthal Chemie Formulacion farmaceutica con liberacion retardada que contiene 3-(3-dimetilamino-1-etil-2-metil-propil) fenol o una sal farmaceuticamente aceptable del mismo y tabletas para administracion oral que la contienen
JP2005526079A (ja) 2002-03-15 2005-09-02 サイプレス バイオサイエンス, インコーポレイテッド 内蔵痛症候群を処置するためのneおよび5−ht再取り込み阻害剤
US20030191187A1 (en) 2002-04-01 2003-10-09 Lee Fang Yu Injectable pharmaceutical composition containing a non-steroidal anti-inflammatory drug and method for preparing the same
EP1545477A4 (en) 2002-09-13 2006-11-22 Cydex Inc CAPSULES CONTAINING AQUEOUS FILLING COMPOSITIONS STABILIZED WITH DERIVED CYCLODEXTRIN
US20040180915A1 (en) 2003-03-14 2004-09-16 Xanodyne Pharmacal, Inc. Methadone-containing compositions for parenteral administration and method of use thereof
WO2005112926A1 (en) 2004-05-17 2005-12-01 Pharmacofore, Inc. Compositions and methods for treating or preventing pain
DE602004007905T2 (de) 2004-06-28 2008-05-08 Grünenthal GmbH Kristalline Formen von (-)-(1R,2R)-3-(3-Dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochlorid
BRPI0513300B1 (pt) 2004-07-01 2018-11-06 Gruenenthal Gmbh forma farmacêutica oral, protegida frente ao abuso, contendo (1r, 2r)-3-(3-dimetilamino-1-etil-2- metil-lpropil)-fenol
CN101208081A (zh) 2005-04-28 2008-06-25 谢拉奎斯特生物科学有限公司 治疗疼痛的方法和组合物
TWI329334B (en) 2005-12-02 2010-08-21 Chung Shan Inst Of Science Manufacture method of electromagnetic interference layer for the plasma display panel
US20080039405A1 (en) * 2006-04-25 2008-02-14 Croda, Inc. Modification of percutaneous absorption of topically active materials
RU2442576C2 (ru) 2006-04-28 2012-02-20 Грюненталь Гмбх Фармацевтическая комбинация, содержащая 3-(3-диметиламино-1-этил-2-метилпропил)фенол и парацетамол
CN105561311B (zh) 2006-04-28 2019-07-16 格吕伦塔尔有限公司 包含3-(3-二甲基氨基-1-乙基-2-甲基-丙基)-苯酚和nsaid的药物组合物
WO2008012283A1 (en) 2006-07-24 2008-01-31 Janssen Pharmaceutica Nv Preparation of (2r,3r)-3-(3-methoxyphenyl)-n,n,2-trimethylpentanamine
DE102007012165A1 (de) 2007-03-12 2008-09-18 Grünenthal GmbH Verwendung von 1-Phenyl-3-dimethylamino-propanverbindungen zur Therapie des Neuropathieschmerzes
EP1985292A1 (en) 2007-04-23 2008-10-29 Grünenthal GmbH Titration of tapentadol
CN102908339A (zh) * 2007-11-23 2013-02-06 格吕伦塔尔有限公司 他喷他多组合物
KR101616246B1 (ko) 2008-01-25 2016-05-02 그뤼넨탈 게엠베하 약제학적 투여형
BRPI0921725A2 (pt) 2008-10-30 2016-01-05 Grüenthal GmbH formas de dosagem potentes do tapentadol
WO2010100477A2 (en) 2009-03-03 2010-09-10 Shire Llc Amino acid and peptide carbamate prodrugs of tapentadol and uses thereof
US20100272815A1 (en) 2009-04-28 2010-10-28 Actavis Group Ptc Ehf Amorphous form of tapentadol hydrochloride
US20110190267A1 (en) * 2010-01-05 2011-08-04 Shire Pharmaceuticals, Inc. Prodrugs of opioids and uses thereof
EP2552486B1 (en) * 2010-03-30 2020-08-12 Phosphagenics Limited Transdermal delivery patch
GB201006200D0 (en) 2010-04-14 2010-06-02 Ayanda As Composition
US20120270848A1 (en) * 2010-10-22 2012-10-25 Galleon Pharmaceuticals, Inc. Novel Compositions and Therapeutic Methods Using Same
RS56692B1 (sr) 2011-03-04 2018-03-30 Gruenenthal Gmbh Polučvrsta vodena farmaceutska kompozicija koja sadrži tapentadol

Also Published As

Publication number Publication date
EA201600442A1 (ru) 2017-02-28
KR101911362B1 (ko) 2018-10-25
EP3766489A1 (en) 2021-01-20
CA2828637C (en) 2019-06-11
CA2828637A1 (en) 2012-09-13
ES2654407T3 (es) 2018-02-13
ZA201306480B (en) 2014-05-28
IL227826A0 (en) 2013-09-30
US20180133174A1 (en) 2018-05-17
JP6259042B2 (ja) 2018-01-10
JP2014506900A (ja) 2014-03-20
AU2012224954B2 (en) 2016-10-20
SI2680834T1 (en) 2018-01-31
EA033171B1 (ru) 2019-09-30
PL2680834T3 (pl) 2018-03-30
PT3766489T (pt) 2022-04-07
EP3766489B1 (en) 2022-03-16
HRP20171836T1 (hr) 2017-12-29
AU2012224954C1 (en) 2017-04-06
MX344473B (es) 2016-12-16
DK2680834T3 (en) 2017-12-04
LT2680834T (lt) 2018-01-10
BR112013022556A2 (pt) 2016-12-06
MX2013010100A (es) 2013-10-01
US20160346229A1 (en) 2016-12-01
IL258357A (en) 2018-05-31
EP3290029A1 (en) 2018-03-07
KR20140013020A (ko) 2014-02-04
MX374468B (es) 2025-03-06
IL227826B (en) 2018-04-30
PT2680834T (pt) 2018-01-25
WO2012119729A1 (en) 2012-09-13
ES2910085T3 (es) 2022-05-11
US9446008B2 (en) 2016-09-20
CN103501774A (zh) 2014-01-08
US20120225950A1 (en) 2012-09-06
EP3290029B1 (en) 2020-09-02
KR20180116463A (ko) 2018-10-24
JP2017039756A (ja) 2017-02-23
EP2680834B1 (en) 2017-10-18
JP2018065839A (ja) 2018-04-26
EA025194B1 (ru) 2016-11-30
KR102039320B1 (ko) 2019-11-01
EA201300988A1 (ru) 2014-06-30
BR112013022556A8 (pt) 2018-01-16
EP2680834A1 (en) 2014-01-08
HUE037491T2 (hu) 2018-09-28
JP6027549B2 (ja) 2016-11-16
RS56692B1 (sr) 2018-03-30
AU2012224954A1 (en) 2013-09-19
JP6670283B2 (ja) 2020-03-18
AU2017200040B2 (en) 2018-09-06
CY1119725T1 (el) 2018-06-27
AU2017200040A1 (en) 2017-02-02

Similar Documents

Publication Publication Date Title
BR112013022641A2 (https=)
BR122019023720A2 (https=)
BR112013027245A2 (https=)
BR112013024383A2 (https=)
BR112013023185A2 (https=)
BR112013022995A2 (https=)
BR112013017670A2 (https=)
BR112013026744A2 (https=)
AP3853A (https=)
BR112013023927A2 (https=)
BR112013024365A2 (https=)
AP2016009466A0 (https=)
BR112013026790A2 (https=)
BR112013024588A2 (https=)
BR112013032368A2 (https=)
BR112013032380A2 (https=)
BR112013032377A2 (https=)
BR112013026895A2 (https=)
BR112013018949A2 (https=)
BR112013021637A2 (https=)
BR112013025487A2 (https=)
BR112013023266A2 (https=)
BR112013032392A2 (https=)
NO2680834T3 (https=)
BR112013017878A2 (https=)